D. E. Shaw & Co., Inc. Apellis Pharmaceuticals, Inc. Call Options Transaction History

D. E. Shaw & Co., Inc.

4 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$28.84 - $41.15 $92,288 - $131,680	-3,200 Reduced 9.17%	31,700 $914,000
Q2 2024 Aug 14, 2024	SELL	$38.07 - $59.71 $106,596 - $167,188	-2,800 Reduced 7.43%	34,900 $1.34 Million
Q1 2024 May 15, 2024	BUY	$55.39 - $72.47 $454,198 - $594,254	8,200 Added 27.8%	37,700 $2.22 Million
Q2 2023 Aug 14, 2023	BUY	$76.68 - $93.31 $2.26 Million - $2.75 Million	29,500 New	29,500 $2.69 Million

308

115M

3.85M

1.09M

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.64B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.